这一数据不仅印证了mRNA肿瘤疫苗能够提供持久免疫应答的科学假设，也为个体化肿瘤疫苗的市场前景提供了有力佐证，同时进一步增强了资本市场对个性化癌症治疗赛道成长性的关注。受消息影响，莫德纳当天股价上涨2.8%，随着mRNA产品临床推进，其股价重拾升势，最新价已逼近近一年高点。据悉，莫德纳已将该疫苗列为预计2027年上线的主要增长驱动力之一。

Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...

If you think last week's decision by the federal government to halt $500 million in funding for vaccine development projects that use mRNA technology will only affect COVID vaccines, think again.

Lipid nanoparticles, such as the one shown in this illustration, are used as vehicles to deliver mRNA-based vaccines. The U.S. Department of Health and Human Services announced on Tuesday that it will ...

Researchers in Philadelphia reacted with alarm this week when the Department of Health and Human Services announced it is cutting $500 million in funding for mRNA vaccine development. But the cuts ...

Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage” of the revenue generated by Spikevax ...

The United States is turning its back on what could be the greatest medical advance in a generation — vaccines made with messenger RNA, or mRNA, technology. The U.S. Department of Health and Human ...